RECORD // Company
Stoke Therapeutics, Inc.
Formerly: ASOthera Pharmaceuticals, Inc.
Built 2026-11-22T05:17:37Z from public sources · JSON · Open the company profile
ASK THE RECORDS
Ask
COMPANY
Records for this company (2 joined by official identifier)
Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.
Gleif lei (1)
- STOKE THERAPEUTICS, INC. · legal entity in this company's GLEIF ownership tree (LEI 549300RD25SS2DIJHJ67)
SEC EDGAR (1)
- Stoke Therapeutics, Inc. · the SEC registrant record of this company
Matched by name only, not merged (2)
These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).
- Stoke Therapeutics, Inc · Ctgov · same registered legal name as 'Stoke Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
- STOKE THERAPEUTICS · Epa echo · exact name match to 'Stoke Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
4 VALUES · 10-Q · EACH LINKS TO ITS FILING
Latest quarter
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-03 · accession 0001193125-26-445326
| Item | Value | Period | Form | Filed | Accession | Report | |
|---|---|---|---|---|---|---|---|
| Revenue | $11,255,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001193125-26-445326 | 2026-11-22 05:17 UTC | Report an error |
| Net income (loss) | $-73,644,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001193125-26-445326 | 2026-11-22 05:17 UTC | Report an error |
| Interest expense | $20,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001193125-26-445326 | 2026-11-22 05:17 UTC | Report an error |
| Cash and cash equivalents | $107,271,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001193125-26-445326 | 2026-11-22 05:17 UTC | Report an error |
Negative as reported in the filing.
Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.
IDS
Identifiers
- SEC CIK
- 0001623526
- Ticker
- STOK
- EIN
- 471144582
- CUSIP
- 86150R107
- Record ID
- sx:sec:0001623526
OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA
Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
33 FACTS · EACH LINKS TO ITS FILING
Facts
| Fact | Value | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 05:17 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 05:17 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 05:17 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 05:17 UTC | Report an error |
| Business address | 45 WIGGINS AVENUE, BEDFORD, MA, 01730 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 05:17 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 05:17 UTC | Report an error |
| Revenue (fiscal year ended 2025-12-31) | $184,420,000 | 2025-12-31 | 10-K, XBRL Revenues | 2026-11-22 05:17 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $-6,885,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | 2026-11-22 05:17 UTC | Report an error |
| Total assets (at 2025-12-31) | $418,434,000 | 2025-12-31 | 10-K, XBRL Assets | 2026-11-22 05:17 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $352,457,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | 2026-11-22 05:17 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $84,220,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | 2026-11-22 05:17 UTC | Report an error |
| Operating cash flow (fiscal year ended 2025-12-31) | $45,585,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | 2026-11-22 05:17 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $670,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | 2026-11-22 05:17 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $4,148,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | 2026-11-22 05:17 UTC | Report an error |
| Form D total offering amount (D filed 2018-11-02) | $90,000,000 | 2018-11-02 | D | 2026-11-22 05:17 UTC | Report an error |
| Form D total amount sold (D filed 2018-11-02) | $90,000,000 | 2018-11-02 | D | 2026-11-22 05:17 UTC | Report an error |
| Form D industry group | Biotechnology | 2018-11-02 | D | 2026-11-22 05:17 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2018-11-02 | D | 2026-11-22 05:17 UTC | Report an error |
| Form D date of first sale | 2018-10-22 | 2018-11-02 | D | 2026-11-22 05:17 UTC | Report an error |
| 8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-29) | On October 29, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter end September 30, 2026. | 2026-10-29 | SEC EDGAR 8-K 0001193125-26-437775 (text as filed, excerpt) | 2026-11-22 05:17 UTC | Report an error |
| 8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-03) | On August 3, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter end June 30, 2026. | 2026-08-03 | SEC EDGAR 8-K 0001193125-26-330537 (text as filed, excerpt) | 2026-11-22 05:17 UTC | Report an error |
| Plan (pension, plan no. 001) | STOKE THERAPEUTICS, INC. 401(K) RETIREMENT PLAN: 202 participants, assets $20,496,166 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | 2026-11-22 05:17 UTC | Report an error |
| Plan (welfare, plan no. 501) | STOKE THERAPEUTICS GROUP HEALTH AND WELFARE PLAN: 170 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #1 (13F as filed): BlackRock, Inc. | $192,307,120 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #2 (13F as filed): RTW INVESTMENTS, LP | $184,001,738 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #3 (13F as filed): FMR LLC | $173,844,632 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #4 (13F as filed): Lynx1 Capital Management LP | $132,136,579 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #5 (13F as filed): Redmile Group, LLC | $129,110,502 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #6 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP | $115,151,528 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #7 (13F as filed): BAKER BROS. ADVISORS LP | $109,176,726 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #8 (13F as filed): TORONTO DOMINION BANK | $103,829,002 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #9 (13F as filed): STATE STREET CORP | $93,325,293 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
| Largest institutional holder #10 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC | $84,644,579 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 05:17 UTC | Report an error |
EVERY DATED RECORD, NEWEST FIRST
Timeline
- 2026-11-03 Filing 10-Q filed
- 2026-10-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-14 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-09-25 Filing 8-K filed: Item 5.02 officer or director change
- 2026-08-03 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-03 Filing 424B5 filed
- 2026-08-03 Filing S-8 filed
- 2026-08-03 Filing 10-Q filed
- 2026-08-03 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-21 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-30 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-04 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-04-22 Filing ARS filed
- 2026-04-22 Filing DEFA14A filed
- 2026-04-22 Filing DEF 14A filed
- 2026-04-07 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-27 Filing 8-K filed: Item 4.01 auditor change; Item 9.01 exhibits
- 2026-03-18 Filing S-3ASR filed
- 2026-03-16 Filing S-8 filed
- 2026-03-16 Filing 10-K filed
- 2026-03-03 Filing 8-K filed: Item 5.02 officer or director change
- 2026-01-26 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation
- 2026-01-12 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2025-12-05 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2025-11-04 Filing 10-Q filed
- 2019-01-15 Record plan effective date: STOKE THERAPEUTICS, INC. 401(K) RETIREMENT PLAN
- 2019-01-01 Record plan effective date: STOKE THERAPEUTICS GROUP HEALTH AND WELFARE PLAN
WHAT IS NOT HERE
Gaps
- Court records: not covered yet (expected 11-19).
- No H-1B LCA filed under EIN 471144582 in FY2026 Q3
- H-1B LCAs only (H-1B1 and E-3 excluded); one fiscal quarter (FY2026 Q3) only, earlier quarters not loaded
- Plan year 2025 only (EFAST2 'Latest' file); earlier years not loaded
- Administrator, signer and preparer names are not kept; sponsor (employer) name only
- Total assets shown only where the plan attached Schedule H (small plans file Schedule I or none)
- Participants: counts at the beginning and at the end of the plan year (end of year includes active, retired and separated participants)
- No Form 990 found for EIN 471144582
- USAspending: no recipient whose SAM legal name and address match this SEC filer
SOURCES AND LICENSE
Sources
- SEC EDGAR: checked · 2026-11-22T05:17:37Z
- DOL OFLC LCA Disclosure Data: checked, nothing found · 2026-11-22T05:17:38Z
- DOL EBSA Form 5500 public datasets: checked · 2026-11-22T05:17:38Z
- Propublica 990: checked, nothing found · 2026-11-22T05:17:38Z
- SEC 13F holdings: checked · 2026-11-22T05:17:39Z
- USAspending: checked, nothing found · 2026-11-22T05:17:40Z
CC BY 4.0 -- credit Seraphix Systems.
API
Use this record
Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.